Advertisement

Molecular Medicine

, Volume 20, Issue 1, pp 503–515 | Cite as

Hydrogen Sulfide Alleviates Myocardial Collagen Remodeling in Association with Inhibition of TGF-β/Smad Signaling Pathway in Spontaneously Hypertensive Rats

  • Lili Sun
  • Hongfang Jin
  • Lujing Sun
  • Siyao Chen
  • Yaqian Huang
  • Jia Liu
  • Zhenzhen Li
  • Manman Zhao
  • Yan Sun
  • Chaoshu Tang
  • Bin Zhao
  • Junbao Du
Research Article

Abstract

The study was designed to explore the role and possible mechanisms of hydrogen sulfide (H2S) in the regulation of myocardial collagen remodeling in spontaneously hypertensive rats (SHRs). We treated nine-week-old male SHRs and age- and sex-matched Wistar-Kyoto rats (WKYs) with NaHS (90 µmol/kg−1-day−1) for 9 wks. At 18 wks, plasma H2S, tail arterial pressure, morphology of the heart, myocardial ultrastructure and collagen volume fraction (CVF), myocardial expressions of collagen I and III protein and procollagen I and III mRNA, transforming growth factor-β1 (TGF-β1), TGF-β type I receptor (TβR-I), type II receptor (TβR-II), p-Smad2 and 3, matrix metalloproteinase (MMP)-13 and tissue inhibitors of MMP (TIMP)-1 proteins were determined. TGF-β 1-stimulated cultured cardiac fibroblasts (CFs) were used to further study the mechanisms. The results showed that compared with WKYs, SHRs showed a reduced plasma H2S, elevated tail artery pressure and increased myocardial collagen, TGF-β1, TβR-II, p-Smad2 and p-Smad3 expressions. However, NaHS markedly decreased tail artery pressure and inhibited myocardial collagen, TGF-β1, TβR-II, p-Smad2 and p-Smad3 protein expressions, but H2S had no effect on the expressions of MMP-13 and TIMP-1. Hydralazine reduced blood pressure but had no effect on myocardial collagen, MMP-13 and TIMP-1 expressions and TGF-β1/Smad signaling pathway. H2S prevented activation of the TGF-β1/Smad signaling pathway and abnormal collagen synthesis in CFs. In conclusion, the results suggested that H2S could prevent myocardial collagen remodeling in SHR. The mechanism might be associated with inhibition of collagen synthesis via TGF-β1/Smad signaling pathway.

Notes

Acknowledgments

This work was supported by the Major Basic Research Development Program of People’s Republic of China (2012CB517806, 2013CB933801 and 2011CB503904), National Natural Science Foundation of China (31130030, 81370154, 81100181 and 81121061), Beijing Natural Science Foundation (7122184 and 7121014) and The Open Project of Key Laboratory of Remodelingrelated Cardiovascular Diseases, Ministry of Education (2014XXGB02).

references

  1. 1.
    Hackam DG, et al. (2010) The 2010 Canadian Hypertension Education Program recommendations for the management of hypertension: part 2-therapy. Can. J. Cardiol. 26:249–58.CrossRefPubMedPubMedCentralGoogle Scholar
  2. 2.
    Laviades C, Mayor G, Diez J. (1994) Treatment with lisinopriol normalizes serum concentrations of procollagen type III amino-terminal peptides in patients with essential hypertension. Am. J. Hypertens. 7:52–8.CrossRefPubMedGoogle Scholar
  3. 3.
    Seeland U, et al. (2002) Myocardial fibrosis in transforming growth factor beta(1)(TGF-beta(1)) transgenic mice is associated with inhibition of interstitial collagenase. Eur. J. Clin. Invest. 32:295–303.CrossRefPubMedGoogle Scholar
  4. 4.
    Tsuda T, et al. (2003) Post-ischemic myocardial fibrosis occurs independent of hemodynamic changes. Cardiovasc. Res. 59:926–33.CrossRefPubMedGoogle Scholar
  5. 5.
    Opie LH, Commerford PJ, Gersh BJ, Pfeffer MA. (2006) Controversies in ventricular remodelling. Lancet. 367:356–67.CrossRefPubMedGoogle Scholar
  6. 6.
    Verrecchia F, Mauviel A. (2007) Transforming growth factor-beta and fibrosis. World J. Gastroenterol. 13:3056–62.CrossRefPubMedPubMedCentralGoogle Scholar
  7. 7.
    Huh MI, et al. (2009) Distribution of TGF-beta isoforms and signaling intermediates in corneal fibrotic wound repair. J. Cell. Biochem. 108:476–88.CrossRefPubMedGoogle Scholar
  8. 8.
    Deten A, Holzl A, Leicht M, Barth W, Zimmer HG. (2001) Changes in extracellular matrix and in transforming growth factor beta isoforms after coronary artery ligation in rats. J. Mol. Cell. Cardiol. 33:1191–207.CrossRefPubMedGoogle Scholar
  9. 9.
    Petrov VV, Fagard RH, Lijnen PJ. (2002) Stimulation of collagen production by transforming growth factor-beta1 during differentiation of cardiac fibroblasts to myofibroblasts. Hypertension. 39:258–63.CrossRefPubMedGoogle Scholar
  10. 10.
    Stow RC, Mallawaarachchi CM, Weissberg PL. (2003) Migration of adventitia myofibroblasts following vascular balloon injury: insights from in vivo gene transfer to rat carotid arteries. Cardiovasc. Res. 59:212–21.CrossRefGoogle Scholar
  11. 11.
    Bujak M, Frangogiannis NG. (2007) The role of TGF-beta signaling in myocardial infarction and cardiac remodeling. Cardiovasc. Res. 74:184–95.CrossRefPubMedGoogle Scholar
  12. 12.
    Seeland U, et al. (2002) Myocardial fibrosis in transforming growth factor beta(1)(TGF-β1) transgenic mice is associated with inhibition of interstitial collagenase. Eur. J. Clin. Invest. 32:295–303.CrossRefPubMedGoogle Scholar
  13. 13.
    Jin L, et al. (2006) Increased RhoA/Rho-kinase signaling mediates spontaneous tone in aorta from angiotensin II-induced hypertensive rats. J. Pharmacol. Exp. Ther. 318:288–95.CrossRefPubMedGoogle Scholar
  14. 14.
    Schiller M, Javelaud D, Mauviel A. (2004) TGF-beta-induced SMAD signaling and gene regulation: consequences for extracellular matrix remodeling and wound healing. J. Dermatol. Sci. 35:83–92.CrossRefPubMedGoogle Scholar
  15. 15.
    Mauviel A. (2005) Transforming growth factor-beta: a key mediator of fibrosis. Methods Mol. Med. 117:69–80.PubMedGoogle Scholar
  16. 16.
    Leask A. (2007) TGFβ, cardiac fibroblasts, and the fibrotic response. Cardiovasc. Res. 74:207–12.CrossRefPubMedGoogle Scholar
  17. 17.
    Li P, et al. (2008) Atrial natriuretic peptide inhibits transforming growth factor β-induced smad signaling and myofibroblast transformation in mouse cardiac fibroblasts. Circ. Res. 102:185–92.CrossRefPubMedGoogle Scholar
  18. 18.
    Shi Y, Massagué J. (2003) Mechanisms of TGF-β signaling from cell membrane to the nucleus. Cell. 113:685–700.CrossRefPubMedGoogle Scholar
  19. 19.
    Bertolino P, Deckers M, Lebrin F, Dijke P. (2005) Transforming growth factor- β signal transduction in angiogenesis and vascular disorders. Chest. 128:585S–90S.CrossRefPubMedGoogle Scholar
  20. 20.
    Lei B, et al. (2011) Effect of efonidipine on tgf-β1-induced cardiac fibrosis through smad2-dependent pathway in rat cardiac fibroblasts. J. Pharmacol. Sci. 7:1–8.Google Scholar
  21. 21.
    Wang R. (2002) Two’s company, three’s a crowd: can H2S be the third endogenous gaseous transmitter. FASEB J. 16:1792–8.CrossRefPubMedPubMedCentralGoogle Scholar
  22. 22.
    Szabo C. (2007) Hydrogen sulphide and its therapeutic potential. Nat. Rev. Drug. Discov. 6: 917–35.CrossRefPubMedPubMedCentralGoogle Scholar
  23. 23.
    Hart JL. (2011) Role of sulfur-containing gaseous substances in the cardiovascular system. Front. Biosci. (Elite Ed.). 3:736–49.CrossRefGoogle Scholar
  24. 24.
    Kabil O, Banerjee R. (2010) Redox biochemistry of hydrogen sulfide. J.Biol. Chem. 285:21903–7.CrossRefPubMedPubMedCentralGoogle Scholar
  25. 25.
    Kimura H. (2013) Production and physiological effects of hydrogen sulfide. Antioxid. Redox Signal. 20:783–93.CrossRefPubMedGoogle Scholar
  26. 26.
    Kimura H, Shibuya N, Kimura Y. (2012) Hydrogen sulfide is a signaling molecule and a cytoprotectant. Antioxid. Redox Signal. 17:45–57.CrossRefPubMedPubMedCentralGoogle Scholar
  27. 27.
    Baskar R, Bian J. (2011) Hydrogen sulfide gas has cell growth regulatory role. Eur. J. Pharmacol. 656:5–9.CrossRefPubMedGoogle Scholar
  28. 28.
    Liu YH, Yan CD, Bian JS. (2011) Hydrogen sulfide: a novel signaling molecule in the vascular system. J. Cardiovasc. Pharmacol. 58:560–9.CrossRefPubMedGoogle Scholar
  29. 29.
    Bian JS, et al. (2006) Role of hydrogen sulfide in the cardioprotection caused by ischemic preconditioning in the rat heart and cardiac myocytes. J. Pharmacol. Exp. Ther. 316:670–8.CrossRefPubMedGoogle Scholar
  30. 30.
    Yan H, Du J, Tang C. (2004) The possible role of hydrogen sulfide on the pathogenesis of spontaneous hypertension in rats. Biochem. Biophys. Res. Commun. 313:22–7.CrossRefPubMedGoogle Scholar
  31. 31.
    Institute of Laboratory Animal Resources (U.S.), Committee on Care and Use of Laboratory Animals. (1985) Guide for the Care and Use of Laboratory Animals. Rev. 1985. Bethesda (MD): NIH. 83 pp. (NIH publication; no. 85-23).Google Scholar
  32. 32.
    Weibel ER, Staubli W, Gnagi HR, Hess FA. (1969) Correlated morphometric and biochemical studies on the liver cell. I. Morphometric model, stereologic methods, and normal morphometric data for rat liver. J. Cell Biol. 42: 68–91.CrossRefPubMedPubMedCentralGoogle Scholar
  33. 33.
    Nouette-Gaulain K, et al. (2005) Time course of differential mitochondrial energy metabolism adaptation to chronic hypoxia in right and left ventricles. Cardiovasc. Res. 66: 132–40.CrossRefPubMedGoogle Scholar
  34. 34.
    Coletta C, Szabo C. (2013) Potential role of hydrogen sulfide in the pathogenesis of vascular dysfunction in septic shock. Curr. Vasc. Pharmacol. 11:208–21.PubMedGoogle Scholar
  35. 35.
    Szabó C, Papapetropoulos A. (2011) Hydrogen sulphide and angiogenesis: mechanisms and applications. Br. J. Pharmacol. 164:853–65.CrossRefPubMedPubMedCentralGoogle Scholar
  36. 36.
    Shi YX, et al. (2007) Chronic sodium hydrosulfide treatment decreases medial thickening of intramyocardial coronary arterioles, interstitial fibrosis, and ROS production in spontaneously hypertensive rats. Am. J. Physiol. Heart Circ. Physiol 293:H2093–100.CrossRefPubMedGoogle Scholar
  37. 37.
    Pitcher TL, Wickens JR, Reynolds JN. (2007) Differences in striatal spiny neuron actinpotentials between the spontaneously hypertensive and Wistar-Kyoto rat strains. Neuroscience. 146:135–42.CrossRefPubMedGoogle Scholar
  38. 38.
    Wang M, et al. (2010) Involvement of NADPH oxidase in age-associated cardiac remodeling. J. Mol. Cell. Cardiol. 48:765–72.CrossRefPubMedPubMedCentralGoogle Scholar
  39. 39.
    Hao J, et al. (1999) Elevation of expression of Smads 2, 3, and 4, decorin and TGF-beta in the chronic phase of myocardial infarct scar healing. J. Mol. Cell. Cardiol. 31:667–78.CrossRefPubMedGoogle Scholar
  40. 40.
    Mori S, et al. (2012) Expression and roles of MMP-2, MMP-9, MMP-13, TIMP-1, and TIMP-2 in allergic nasal mucosa. Allergy Asthma Immunol. Res. 4:231–9.CrossRefPubMedPubMedCentralGoogle Scholar
  41. 41.
    Cevik C, et al. (2011) Rosuvastatin therapy does not affect serum MMP-13 or TIMP-1 levels in hypercholesterolemic patients. Tex. Heart Inst. J. 38:229–33.PubMedPubMedCentralGoogle Scholar

Copyright information

© The Author(s) 2014

Open Access This article is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License, which permits any non-commercial use, sharing, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, and provide a link to the Creative Commons license. You do not have permission under this license to share adapted material derived from this article or parts of it.

The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder.

To view a copy of this license, visit (https://doi.org/creativecommons.org/licenses/by-nc-nd/4.0/)

Authors and Affiliations

  • Lili Sun
    • 1
  • Hongfang Jin
    • 2
    • 3
  • Lujing Sun
    • 1
  • Siyao Chen
    • 2
  • Yaqian Huang
    • 2
  • Jia Liu
    • 2
  • Zhenzhen Li
    • 2
  • Manman Zhao
    • 2
  • Yan Sun
    • 2
  • Chaoshu Tang
    • 4
    • 5
  • Bin Zhao
    • 1
  • Junbao Du
    • 2
  1. 1.Department of Emergency MedicineBeijing Jishuitan HospitalBeijingChina
  2. 2.Department of PediatricsPeking University First HospitalBeijingChina
  3. 3.Key Laboratory of Remodeling-Related Cardiovascular Diseases, Ministry of Education, Beijing Institute of Heart, Lung and Blood Vessel DiseasesBeijing An Zhen Hospital, Capital Medical UniversityBeijingChina
  4. 4.Department of Physiology and PathophysiologyPeking University Health Science CenterBeijingChina
  5. 5.Key Laboratory of Molecular Cardiovascular SciencesMinistry of EducationBeijingChina

Personalised recommendations